MetaCap

Coherus Oncology (CHRS) vs Champions Oncology (CSBR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Champions Oncology (CSBR) has outperformed Coherus Oncology (CHRS) over the past year, losing 35.9% versus a loss of 68.1%. Over five years, CSBR leads with a -53.0% price change compared with -98.0% for CHRS. Champions Oncology is the larger company by market cap ($60.4 million vs $57.1 million), about 1.1 times the size, while Coherus Oncology is growing revenue faster (+59.8% vs +4.4%).

Coherus Oncology converts more of its revenue into profit, with a net margin of 398.4% versus -2.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CHRS-68.12%CSBR-35.89%
+126%+24%-77%
Nov 21, 20251 yearNov 20, 2026
CHRS-98.00%CSBR-53.68%
+30%-37%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CHRS versus CSBR key metrics
MetricCHRSCSBR
Share price$0.3698$4.34
Market cap$57.15M$60.41M
1-day change-4.47%-1.36%
YTD return-73.96%-37.19%
1-year return-68.12%-35.89%
5-year return-97.99%-52.98%
Forward P/E—43.40
EPS (TTM)$-1.12$-0.07
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$42.17M$59.42M
Revenue growth (YoY)+59.81%+4.36%
Net income (latest FY)$168.02M$-1.18M
Gross margin67.24%48.00%
Operating margin-429.51%-1.92%
Net margin398.43%-1.98%
52-week high$2.62$8.31
52-week low$0.3628$4.34
Distance from 52-week high-85.86%-47.77%
Analyst consensusstrong_buy—
Avg. price target upside+1995.73%—
Average volume1.80M9.71K
Shares outstanding154.54M13.92M
Employees144214
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CSBR has outperformed CHRS by 32.2 percentage points over the past year.
  • Coherus Oncology is more profitable, keeping 398.4 cents of every revenue dollar as net income versus -2.0 cents for Champions Oncology.
  • Coherus Oncology grew revenue faster in its latest fiscal year (+59.81% vs +4.36%).

About Coherus Oncology

CHRS stock →

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees

About Champions Oncology

CSBR stock →

Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 214 employees

CHRS vs CSBR FAQ

Which is bigger, Coherus Oncology or Champions Oncology?

Champions Oncology (CSBR) is larger, with a market capitalization of $60.41M compared with $57.15M for Coherus Oncology (CHRS).

Which stock has performed better over the past year, CHRS or CSBR?

CSBR returned -35.89% over the past 12 months, compared with -68.12% for CHRS (price return, excluding dividends). Past performance does not predict future results.

Are Coherus Oncology and Champions Oncology in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons